Andere Sprachen Tenaya Therapeutics, Inc.

Aktien

A3CWF0

US87990A1060

TNYA

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:11:49 30.04.2024			% 5 Tage	% 1. Jan.
4,61 ^USD	+1,54 %		+3,15 %	+41,67 %

21.03.	TENAYA THERAPEUTICS, INC. : Canaccord Genuity bekräftigt seine Kaufempfehlung	ZM
18.03.	Tenaya Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Stock Futures -2-	19.03.
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18.03.
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	18.03.
Tenaya Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18.03.
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	18.03.
Tenaya Therapeutics, Inc. Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	18.03.
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences	27.02.
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications	26.02.
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications	26.02.
Tenaya Therapeutics Insider Bought Shares Worth $9,999,999, According to a Recent SEC Filing	14.02.
Tenaya Therapeutics Announces Pricing of Underwritten Offering	08.02.
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference	03.01.
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference	21.11.
Tenaya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	08.11.
Tenaya Therapeutics Gets FDA Clearance For TN-401 Gene Therapy Trial	26.10.23
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy	26.10.23
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy	26.10.23
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting	09.10.23
Tenaya Therapeutics, Inc. Releases New Data for Tn-301 At the 2023 Heart Failure Society of America	09.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tenaya Therapeutics, Inc.

Aktien

A3CWF0

US87990A1060

TNYA

Andere Sprachen

Filter